CASI Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products in China, the United States, and throughout the world.
Company profile
Ticker
CASI
Exchange
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
CASI Pharmaceuticals Holdings, Inc.
SEC CIK
CASI stock data
Latest filings (excl ownership)
F-3
Shelf registration (foreign)
3 May 24
6-K
Current report (foreign)
8 Apr 24
6-K
Casi Pharmaceuticals Announces Fourth Quarter and Full-year 2023 Business and Financial Results
28 Mar 24
20-F
2023 FY
Annual report (foreign)
28 Mar 24
6-K
Current report (foreign)
13 Mar 24
6-K
Current report (foreign)
29 Feb 24
6-K
Current report (foreign)
9 Feb 24
6-K
Current report (foreign)
30 Jan 24
6-K
Current report (foreign)
15 Dec 23
6-K
Current report (foreign)
8 Dec 23
Financial summary
Quarter (USD) | Dec 22 | |
---|---|---|
Revenue | ||
Cost of revenue | ||
Operating income | ||
Operating margin | ||
Net income | ||
Net profit margin | ||
Cash on hand | ||
Change in cash | ||
Diluted EPS |
Annual (USD) | Dec 22 | |
---|---|---|
Revenue | ||
Cost of revenue | ||
Operating income | ||
Operating margin | ||
Net income | ||
Net profit margin | ||
Cash on hand | ||
Change in cash | ||
Diluted EPS |
Institutional ownership, Q4 2023
25.5% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 2 |
Opened positions | 0 |
Closed positions | 19 |
Increased positions | 1 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 3.42 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Huang James | 2.33 mm | $0.00 |
He Wei-Wu | 1.10 mm | $0.00 |
News
CASI Pharmaceuticals Discloses Material Development Relating To Its Dispute With Juventas
8 Apr 24
CASI Pharmaceuticals Wins Emergency Relief Regarding the Dispute with Juventas Cell Therapy Ltd Prohibiting Juventas from Commercializing CNCT19
8 Apr 24
CASI Pharmaceuticals Q4 EPS $(0.45) Misses $(0.24) Estimate, Sales $6.87M Miss $9.41M Estimate
28 Mar 24
Recap: CASI Pharmaceuticals Q4 Earnings
28 Mar 24
CASI Pharmaceuticals FY2023 GAAP EPS $(2.02) Misses $(1.93) Estimate, Sales $33.88M Miss $36.42M Estimate
28 Mar 24
Press releases
CASI PHARMACEUTICALS REPORTS DEVELOPMENT RELATING TO ITS DISPUTES WITH JUVENTAS
8 Apr 24
CASI PHARMACEUTICALS ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2023 BUSINESS AND FINANCIAL RESULTS
28 Mar 24
Thinking about buying stock in Ocean Biomedical, CASI Pharmaceuticals, Cardiol Therapeutics, Geron, or Rocket Pharmaceuticals?
5 Mar 24
CASI PHARMACEUTICALS ANNOUNCES FIRST DOSING OF FOLOTYN® IN CHINA
16 Feb 24